Ever Supreme Bio Technology Co., Ltd (TPEX:6712)
169.00
-1.50 (-0.88%)
At close: Dec 5, 2025
TPEX:6712 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2016 |
| Revenue | 1,006 | 933.81 | 758.39 | 627.51 | 438.84 | 70.6 | Upgrade
|
| Revenue Growth (YoY) | 19.08% | 23.13% | 20.86% | 42.99% | 521.61% | 552.53% | Upgrade
|
| Cost of Revenue | 302.31 | 273.77 | 273.64 | 212.96 | 193.36 | 88.54 | Upgrade
|
| Gross Profit | 703.73 | 660.04 | 484.75 | 414.56 | 245.48 | -17.95 | Upgrade
|
| Selling, General & Admin | 46.24 | 47.18 | 47.91 | 40.07 | 45.14 | 29.91 | Upgrade
|
| Research & Development | 206.31 | 147.22 | 99.11 | 90.69 | 84.14 | 109.25 | Upgrade
|
| Other Operating Expenses | - | 44.38 | - | - | - | - | Upgrade
|
| Operating Expenses | 252.07 | 238.85 | 147.02 | 130.76 | 129.28 | 139.16 | Upgrade
|
| Operating Income | 451.66 | 421.19 | 337.73 | 283.8 | 116.2 | -157.11 | Upgrade
|
| Interest Expense | -0.77 | -0.13 | -0.2 | -0.51 | -0.62 | -0.78 | Upgrade
|
| Interest & Investment Income | 26.15 | 10.89 | 14.18 | 9.88 | 6 | 3.65 | Upgrade
|
| Earnings From Equity Investments | 49.19 | 52.09 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | 21.76 | -30.72 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 29.86 | 23.3 | 7.52 | 7.35 | 4.27 | 2.58 | Upgrade
|
| EBT Excluding Unusual Items | 556.09 | 507.35 | 380.99 | 269.79 | 125.85 | -151.66 | Upgrade
|
| Gain (Loss) on Sale of Investments | 66.04 | -46.68 | 241.86 | -5.7 | 261.05 | 14.31 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -0 | 11.33 | -0.05 | Upgrade
|
| Asset Writedown | - | - | - | - | -1.94 | - | Upgrade
|
| Other Unusual Items | 0 | 0.08 | 0.17 | 0.01 | 0.52 | - | Upgrade
|
| Pretax Income | 622.13 | 460.74 | 623.01 | 264.1 | 396.82 | -137.4 | Upgrade
|
| Income Tax Expense | 101.24 | 93.49 | 83.62 | 63.39 | 27.22 | -30.57 | Upgrade
|
| Net Income | 520.9 | 367.25 | 539.4 | 200.71 | 369.6 | -106.83 | Upgrade
|
| Net Income to Common | 520.9 | 367.25 | 539.4 | 200.71 | 369.6 | -106.83 | Upgrade
|
| Net Income Growth | 104.81% | -31.91% | 168.74% | -45.69% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 88 | 89 | 90 | 91 | 90 | 82 | Upgrade
|
| Shares Outstanding (Diluted) | 88 | 89 | 90 | 91 | 91 | 82 | Upgrade
|
| Shares Change (YoY) | -0.68% | -1.65% | -1.01% | 0.15% | 11.01% | 0.09% | Upgrade
|
| EPS (Basic) | 5.91 | 4.14 | 5.99 | 2.21 | 4.10 | -1.30 | Upgrade
|
| EPS (Diluted) | 5.89 | 4.14 | 5.97 | 2.20 | 4.06 | -1.30 | Upgrade
|
| EPS Growth | 106.31% | -30.75% | 171.70% | -45.83% | - | - | Upgrade
|
| Free Cash Flow | 587.72 | 435.49 | 415.92 | 316.02 | 133.7 | -197.3 | Upgrade
|
| Free Cash Flow Per Share | 6.66 | 4.91 | 4.61 | 3.46 | 1.47 | -2.40 | Upgrade
|
| Dividend Per Share | 4.654 | 4.654 | 4.959 | 1.503 | 3.416 | - | Upgrade
|
| Dividend Growth | -6.15% | -6.15% | 229.89% | -56.00% | - | - | Upgrade
|
| Gross Margin | 69.95% | 70.68% | 63.92% | 66.06% | 55.94% | -25.42% | Upgrade
|
| Operating Margin | 44.90% | 45.11% | 44.53% | 45.23% | 26.48% | -222.54% | Upgrade
|
| Profit Margin | 51.78% | 39.33% | 71.12% | 31.99% | 84.22% | -151.32% | Upgrade
|
| Free Cash Flow Margin | 58.42% | 46.63% | 54.84% | 50.36% | 30.47% | -279.48% | Upgrade
|
| EBITDA | 465.63 | 440.28 | 357.69 | 307.28 | 141.47 | -135.61 | Upgrade
|
| EBITDA Margin | 46.28% | 47.15% | 47.16% | 48.97% | 32.24% | -192.09% | Upgrade
|
| D&A For EBITDA | 13.96 | 19.09 | 19.96 | 23.48 | 25.27 | 21.5 | Upgrade
|
| EBIT | 451.66 | 421.19 | 337.73 | 283.8 | 116.2 | -157.11 | Upgrade
|
| EBIT Margin | 44.90% | 45.11% | 44.53% | 45.23% | 26.48% | -222.54% | Upgrade
|
| Effective Tax Rate | 16.27% | 20.29% | 13.42% | 24.00% | 6.86% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.